The legal landscape surrounding state vapor product directories continues to shift. 

In a significant decision, the U.S. Court of Appeals for the Eighth Circuit has lifted the preliminary injunction that had prevented Iowa from enforcing its vapor products directory law. While the case is far from over, the ruling gives Iowa the ability to move forward with implementation while litigation continues—and sends another signal that courts may be increasingly willing to uphold state directory laws tied to the FDA's PMTA process. 

The dispute centers around Iowa's House File 2677, which requires manufacturers to submit products for inclusion in a state directory before they can legally be sold in Iowa. 

Under the law, manufacturers must: 

• Have an FDA-authorized product or meet specific PMTA eligibility requirements.  

• Submit product information to the state.  

• Pay registration fees for each product.  

• Designate an Iowa agent for service of process.  

A coalition of manufacturers, distributors, retailers, consumers, and advocacy groups challenged the law, arguing that Iowa was attempting to regulate an area reserved exclusively for the FDA. 

A federal district court initially agreed, issuing a preliminary injunction that blocked enforcement while the lawsuit proceeded. 

The Eighth Circuit has now reversed that decision. 

 

Court Says States Can Add Their Own Requirements 

The central legal question was whether Iowa's directory law is preempted by the federal Tobacco Control Act. 

The appellate court concluded that it is not. 

According to the majority opinion, Congress specifically preserved a state's authority to regulate the sale, distribution, and reporting of tobacco products—even when those requirements reference federal authorization standards. 

Rather than viewing Iowa's law as an attempt to enforce federal law, the court characterized it as a state sales law that simply uses federal regulatory status as one of its qualifications. 

In other words, Iowa is not issuing PMTAs or making FDA decisions—it is determining which products may be sold within its borders. 

 

FDA Enforcement Discretion Wasn't Enough 

One of the industry's strongest arguments focused on FDA enforcement discretion. 

The FDA has repeatedly stated that it prioritizes enforcement against certain unauthorized products instead of taking action against every product lacking marketing authorization. 

Plaintiffs argued that Iowa's law effectively overrides that federal approach by creating stricter restrictions than the FDA currently enforces. 

The Eighth Circuit rejected that argument. 

The court explained that federal enforcement priorities are not the same as federal law. While the FDA may choose how aggressively it enforces the Tobacco Control Act, that discretion does not prevent states from adopting their own sales restrictions consistent with existing federal statutes. 

That distinction could become increasingly important as more states adopt PMTA-based directory systems. 

 

Another Court Joins Wisconsin 

The Iowa decision follows a similar appellate ruling involving Wisconsin earlier this year. 

With both the Seventh and Eighth Circuits now allowing state directory laws to move forward against federal preemption challenges, momentum appears to be building in favor of state authority. 

While each state's law differs, these rulings suggest appellate courts are increasingly viewing directory laws as permissible state regulation rather than unlawful interference with FDA authority. 

That trend could influence pending litigation in other states considering or defending similar laws. 

 

The Case Isn't Finished 

Although the injunction has been lifted, the lawsuit itself remains active. 

The Eighth Circuit sent the case back to the federal district court, where additional claims—including constitutional equal protection arguments—will continue to be litigated. 

One member of the three-judge panel also wrote separately to caution that additional factual development may still be necessary before resolving every preemption issue. 

For now, however, Iowa is no longer prevented from enforcing its directory law while those remaining claims proceed. 

 

What This Means for Manufacturers and Retailers 

For businesses operating in Iowa, the immediate impact is clear: the state now has a path to begin enforcing its directory requirements unless another court intervenes. 

More broadly, the decision reinforces an important reality for the vapor industry. 

Even as the FDA continues to refine its national enforcement priorities, states are increasingly establishing their own regulatory frameworks that determine which products may be sold within their borders. 

For manufacturers and distributors, compliance is becoming a state-by-state challenge—not simply a federal one. 

As additional courts weigh similar laws, businesses should expect state directory programs to remain one of the most important regulatory issues affecting the independent vapor industry in the months ahead.